VEGFA and age-related macular degeneration: Intravitreal anti-VEGF agents such as aflibercept (Eylea®), ranibizumab (Lucentis®), bevacizumab (Avastin®) and increasingly faricimab (Vabysmo®) are commonly used in non-pregnant patients for the management of several chorioretinal diseases such as macular neovascularisation (MNV) (related to age-related macular degeneration (AMD), myopia, inflammatory chorioretinal diseases or other secondary causes), DMO, cystoid macular oedema related to retinal vein occlusion, and radiation maculopathy.